National Pension Service Increases Stock Holdings in Axon Enterprise, Inc $AXON

National Pension Service boosted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 195,766 shares of the biotechnology company’s stock after acquiring an additional 2,231 shares during the quarter. National Pension Service’s holdings in Axon Enterprise were worth $140,490,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Westside Investment Management Inc. boosted its stake in shares of Axon Enterprise by 4.8% in the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 13 shares during the period. CVA Family Office LLC boosted its position in Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. boosted its position in Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 14 shares during the last quarter. Vicus Capital grew its stake in shares of Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 14 shares in the last quarter. Finally, Evergreen Capital Management LLC increased its position in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 5.1%

AXON stock opened at $483.58 on Friday. The firm has a market cap of $38.16 billion, a price-to-earnings ratio of 153.03, a PEG ratio of 15.35 and a beta of 1.41. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The firm has a fifty day moving average price of $578.34 and a two-hundred day moving average price of $669.10. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. During the same period last year, the firm posted $1.45 earnings per share. The company’s quarterly revenue was up 30.6% on a year-over-year basis. Research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Activity at Axon Enterprise

In other news, insider Jeffrey C. Kunins sold 1,797 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the sale, the insider directly owned 83,485 shares in the company, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brittany Bagley sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $610.00, for a total value of $1,525,000.00. Following the completion of the sale, the chief financial officer directly owned 91,092 shares in the company, valued at approximately $55,566,120. This trade represents a 2.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 60,540 shares of company stock valued at $34,684,738. 4.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AXON shares. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a research note on Tuesday, January 6th. UBS Group reduced their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada started coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They issued an “outperform” rating and a $860.00 target price for the company. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $805.71.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.